

CD4 cell count and CD4/CD8 ratio increase during rituximab maintenance in granulomatosis with polyangiitis patients

Emilio Besada¹ and Johannes C. Nossent^{2,3}

¹ Bone and Joint Research Group, Institute of Clinical Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway

² School of Medicine & Pharmacology QEII Medical Centre Unit, University of Western Australia, Australia

³ Rheumatology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia

ABSTRACT

Introduction: Rituximab (RTX) is a B cell-depleting agent approved for the treatment of granulomatosis with polyangiitis (GPA). RTX reduces antibody producing precursor plasma cells and inhibits B and T cells interaction. Infections related to T cell immunodeficiency are not infrequent during RTX treatment. Our study investigated CD4 cell count and CD4/CD8 ratio in GPA patients during the first two years of long-term RTX treatment.

Methods: A single centre cohort study of 35 patients who received median total cumulative dose of cyclophosphamide (CYC) of 15 g and were treated with RTX 2 g followed by retreatment with either 2 g once annually or 1 g biannually. Serum levels of total immunoglobulin (Ig) and lymphocytes subsets were recorded at RTX initiation and at 3, 6, 12, 18 and 24 months. Low CD4 count and inverted CD4/CD8 ratio were defined as $CD4 < 0.3 \times 10^9/l$ and ratio < 1 .

Results: The CD4 cell count and CD4/CD8 ratio decreased slightly following the initial RTX treatment and then increased gradually during maintenance treatment. While the proportion of patients with low CD4 cell count decreased from 43% at baseline to 18% at 24 months, the ratio remained inverted in 40%. Oral daily prednisolone dose at baseline, CYC exposure and the maintenance regimen did not influence the CD4 cell count and ratio. Being older ($p = 0.012$) and having a higher CRP ($p = 0.044$) and ESR ($p = 0.024$) at baseline significantly increased the risk of inverted CD4/CD8 ratio at 24 months. Inverted ratio at baseline associated with lower total Ig levels during the study.

Conclusions: Overall, the CD4 and CD4/CD8 ratio increased during maintenance RTX therapy in GPA with no discernible impact of other immunosuppressive therapy. However the increase in CD4 was not followed by an increase in the CD4/CD8 ratio, especially in older patients. Inverted CD4/CD8 ratio associated with lower Ig levels, suggesting a more profound B cell depleting effect of RTX with a relative increase in CD8+ lymphocytes.

Subjects Allergy and Clinical Immunology, Internal Medicine, Rheumatology

Keywords ANCA-associated vasculitis, Rituximab, Granulomatosis with polyangiitis, CD4/CD8 ratio, CD4 cell, CD8 cell, Infection, Immunosuppression, B cell depletion, Hypogammaglobulinemia

Submitted 16 June 2016
Accepted 25 August 2016
Published 20 September 2016

Corresponding author
Emilio Besada, emilio.besada@uit.no

Academic editor
Teresa Seccia

Additional Information and
Declarations can be found on
page 12

DOI 10.7717/peerj.2487

© Copyright
2016 Besada & Nossent

Distributed under
Creative Commons CC-BY 4.0

OPEN ACCESS

INTRODUCTION

Granulomatosis with polyangiitis (GPA) is an antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) resulting in a necrotizing small to medium vessels vasculitis and a necrotizing granulomatous inflammation involving predominantly the upper and lower respiratory tract and the kidneys. GPA is the result of a complex interplay between the humoral and cellular immunity involving proteinase 3-ANCA (PR3-ANCA), neutrophils, endothelial cells, B and T cells ([Kallenberg, 2011](#)).

T cells are important in GPA as persistent activation of T cells through aberrant expression of costimulatory molecules favours the expansion of effector memory T cells and the formation of granuloma ([Wilde et al., 2010](#)). Changes in T cells in GPA patients occur during remission when circulating memory T cells are increased and naive T CD4+ cells are decreased ([Abdulahad et al., 2006](#)). Also, T cell-targeted therapies such as abatacept, alemtuzumab and gusperimus are alternative treatments to B cell depletion with rituximab (RTX) in GPA ([Furuta & Jayne, 2014](#)).

However, a subgroup of GPA patients has low CD4 cell count and inverted CD4/CD8 ratio irrespective of disease activity and the use of immunosuppressive drugs, possibly due to the recruitment of T cells into the inflamed tissue ([Berden et al., 2009](#)). It is not clear whether it is the decrease of CD4 cell count ([Marinaki et al., 2006](#)), the expansion of CD8 cell count or a combination of both ([Ikeda et al., 1992](#); [Iking-Konert et al., 2008](#)) that is responsible for the inversion of the ratio.

RTX is a chimeric human-mouse monoclonal antibody directed against CD20 that induces rapid and sustained depletion of premature and mature B cells through antibody-dependent, complement-mediated cellular cytotoxicity and apoptosis ([Leandro & de la Torre, 2009](#)). RTX reduces auto-antibody producing precursor plasma cells, inhibits B cell interaction with auto reactive T cells and decreases the level of soluble factors secreted by B cells ([Leandro & de la Torre, 2009](#)). RTX is approved for the treatment of rheumatoid arthritis (RA) and AAV and is used off label in a large number of autoimmune conditions ([Edwards & Cambridge, 2006](#)). In AAV, RTX is used to induce ([Jones et al., 2010](#); [Stone et al., 2010](#)) and to maintain ([Guillevin et al., 2014](#); [Smith et al., 2012](#); [Cartin-Ceba et al., 2012](#); [Besada, Koldingsnes & Nossent, 2013](#)) remission through iterative infusions. Relevant side effects of RTX include late onset neutropenia ([Besada, Koldingsnes & Nossent, 2012](#)), hypogammaglobulinemia ([Makatsori et al., 2014](#); [Besada, Koldingsnes & Nossent, 2014](#)) and an increased risk of infections ([Besada, Koldingsnes & Nossent, 2013](#); [Ram et al., 2009](#); [Sailler et al., 2008](#); [Gottenberg et al., 2010](#)). In two studies, 27–44% of all severe infections during RTX treatment were either viral or fungal ([Besada, Koldingsnes & Nossent, 2013](#); [Makatsori et al., 2014](#)), possibly related to T cell immunodeficiency.

Our study investigated the course of CD4 cell count, CD4/CD8 ratio and serum levels of total immunoglobulin (Ig) in GPA patients receiving long-term RTX treatment.

METHODS

The Vasculitis Registry in Northern Norway is an observational prospective registry collecting data on disease presentation and course from patients with an established

diagnosis of primary vasculitis. All patients gave informed written consent at inclusion in accordance with the declaration of Helsinki.


A total of 35 patients from the Vasculitis Registry in Northern Norway with an established diagnosis of GPA were included in the study. The study did not require formal ethical approval and conformed to the standards currently applied in Norway. Patients' characteristics at baseline have been previously described ([Besada, Koldingsnes & Nossent, 2013](#)).

At RTX initiation, the patients (median age of 50 (14–79), 54% males) had median disease duration of 55 months (1–270). However, 86% of the patients were ANCA positive; all except one were PR3-ANCA positive. Renal, lung and orbital or/and subglottic involvement was present in 60, 63 and 57% of the patients. Median Birmingham Vasculitis Activity Score (BVAS) was 9 (0–22) at baseline. The main indication for RTX was disease relapse (80%), new disease onset (17%) and maintenance therapy (3%). Patients had received a median cumulative cyclophosphamide (CYC) dose of 14 g (0–250) prior to RTX and all had normal total Ig levels (> 6 g/l) prior to RTX.

Patients received 2 g RTX at induction (1 g twice in a fortnight) with co-administration of methylprednisolone 125 mg, paracetamol 1,000 mg and either cetirizine 10 mg or polaramine 4 mg. RTX was usually combined with a median oral daily prednisolone dose (ODPD) of 20 mg (0–60) and an immunosuppressive drug in 91% of the patients. Overall, patients received a median cumulative RTX dose of 4 g (2–6) during the first 24 months following its initiation. Respectively 49 and 40% received long-term maintenance with the 2 g annually regimen (1 g twice in a fortnight per year) or the 1 g biannually regimen (1 g every six months), while 11% received only induction.

Clinical parameters such as gender, age, erythrocyte sedimentation rate (ESR, nr: < 20 in men and < 28 mm/h in women), C-reactive protein (CRP, nr < 5 mg/l), creatinine (nr: 60–105 in men and 45–90 μ mol/l in women), ANCA titers (nr < 10 IU/ml), the ODPD and the cumulative dose of CYC were recorded at baseline. Serum levels of total Ig and lymphocytes subsets were measured at RTX initiation and at 3, 6, 12, 18 and 24 months in 35, 24, 31, 34, 31 and 34 patients, respectively. CD4 and CD8 cell counts were determined by flow cytometry in blood specimens. Normal adult CD4 and CD8 cell counts for our laboratory ranged from 0.3–1.4 and 0.2–0.9 $\times 10^9/l$, respectively. Low CD4 cell count was defined as CD4 < 0.3 $\times 10^9/l$ and inverted CD4/CD8 ratio when ratio < 1. Hypogammaglobulinemia was defined as serum total Ig < 6 g/l. Severe infections were defined as infections necessitating intravenous antibiotic treatment and/or hospitalisation.

Data were analysed with SPSS version 20.0 (SPSS Ltd, Chicago, IL, USA). The results are expressed in percentage for categorical variable and in median (range) for continuous variables, unless specified otherwise. Fisher's exact test, Wilcoxon signed rank test and Man-Whitney U test were used as appropriate. Significant predictors of inversion of the CD4/CD8 ratio at 24 months determined during univariable analysis were entered in a multivariable binary logistic regression model with backward selection ($p < 0.05$ to enter and $p < 0.10$ to stay). Missing data were excluded from the statistical analyses. p -values < 0.05 were considered significant.



CD4 cell count x 10 ⁹ /L	0.36 0.22-0.64	0.28 0.17-0.50	0.34 0.27-0.49	0.39 0.29-0.59	0.42 0.30-0.56	0.45 0.33-0.88
CD4/CD8 ratio	1.16 0.85-1.74	0.99 0.54-1.34	1.12 0.71-1.46	1.14 0.75-1.78	1.19 0.82-1.85	1.38 0.61-1.99

Figure 1 CD4 cell count and CD4/CD8 ratio in GPA patients during long-term RTX treatment. Full line: low CD4 cell count. Dashed line: inverted CD4/CD8 ratio. Table results are expressed in median and interquartile range.

RESULTS

CD4 cell count and ratio

Both the CD4 cell count and the CD4/CD8 ratio decreased initially after RTX administration, and thereafter increased gradually (Fig. 1). The CD4 cell count seemed to decrease between baseline and three months ($0.36-0.28 \times 10^9/l$, $p = 0.166$), while the ratio decreased significantly from 1.16 to 0.99 ($p = 0.011$). At 24 months, CD4 cell count and ratio had both significantly increased from baseline: $0.45 \times 10^9/l$ ($p = 0.039$) and 1.38 ($p = 0.031$), respectively.

However, while the proportion of patients with a low CD4 cell count decreased from 43% at baseline to 18% at 24 months, the proportion of patients with inverted ratio remained stable around 40% throughout the study period (Fig. 2).

Baseline clinical profile influence on CD4 cell count and ratio

CD4 cell count and ratio at baseline

Patients with low CD4 cell count and inverted ratio at baseline had a tendency to be older ($p = 0.069$ and $p = 0.057$, respectively) (Tables 1 and 2). Only patients with low CD4 cell count seemed to have a higher cumulative dose of CYC compared with patients with a normal baseline CD4 cell count ($p = 0.071$) (Table 2).

There were no difference in organ involvements, disease duration prior to RTX, BVAS, CRP, ESR, creatinine and ANCA titers at RTX initiation between patients with normal and low CD4 cell count at baseline (Table 1) and patients with normal and inverted ratio (Table 2).




Figure 2 Proportion of GPA patients with low CD4 cell count and inverted ratio during long-term rituximab. Full line: low CD4 cell count. Dashed line: inverted CD4/CD8 ratio. The proportion of patients is expressed in percentage.

CD4/CD8 ratio at 24 months

Patients who had an inverted CD4/CD8 ratio at 24 months were older (60 vs. 45 years, $p = 0.003$), had higher ESR (43 vs. 12 mm/h, $p = 0.009$) and creatinine (82 vs. 67 $\mu\text{mol/l}$, $p = 0.018$) at baseline. Although not significant, they also had a tendency to higher BVAS (11 vs. 8, $p = 0.096$), CRP (24 vs. 6 mg/l, $p = 0.076$) and ANCA titers (16 vs. 5 IU/ml, $p = 0.089$). Being older and having higher CRP and ESR at baseline significantly increased the risk of inverted CD4/CD8 ratio at 24 months during univariable analysis (Table 3). Age was the most important predictor for inversion of the CD4/CD8 ratio at 24 months during the multivariable analysis (Table 3). Being 10 years older at RTX initiation increased the risk by 2.5 times.

Serum immunoglobulin levels

Serum total Ig levels in both patients with low CD4 cell count and inverted ratio were lower at all time points during RTX maintenance (Tables 1 and 2). This was only significant in patients with inverted ratio compared with patients with normal ratio at baseline (Table 2). The different RTX maintenance regimens did not influence CD4 cell count, ratio and total Ig levels in the first two years (Table 4).

Severe infections in the first 24 months after RTX initiation

Two patients (5.7%) had severe infections during the study period three and four months after RTX initiation. One patient had sinusitis secondary to *Pseudomonas aeruginosa* and the other had *Pneumocystis jirovecii* pneumonia. They were men, aged 62 and 79 years old, who had received 250 and 25 g of CYC. They had low B cell (0.04 and $0.06 \times 10^9/l$) and CD4 cell counts (0.17 and $0.26 \times 10^9/l$), inverted ratio (0.35 and 0.43), but had

Table 1 Characteristics of GPA patients with low CD4 cell count at baseline against the rest of the cohort. Results are expressed in number (percentage) for categorical variables and median (range) for continuous variables. Differences were determined respectively by Fisher's exact test and Mann Whitney U test. Serum total immunoglobulin level and CD4 cell count expressed respectively in g/L and $\times 10^9/L$. Significant results are highlighted in bold.

	Low CD4 count 15 patients	Normal CD4 count 20 patients	p-value
Male	9 (40%)	10 (50%)	0.784
Age y	58 (19–79)	47 (14–67)	0.069
Disease duration prior RTX mo	93 (2–270)	45 (1–198)	0.254
BVAS at baseline	11 (4–21)	8.5 (0–21)	0.657
ESR mm/t	15 (3–118)	17 (7–100)	0.400
CRP mg/L	6 (4–135)	7.5 (4–127)	0.908
Creatinine $\mu\text{mol/L}$	75 (46–244)	77 (43–819)	0.934
ANCA titers IU/L	7 (0–531)	8 (1–109)	0.780
Kidney involvement	8 (53%)	13 (65%)	0.511
Lung involvement	10 (67%)	12 (60%)	0.737
Orbital-subglottic involvement	10 (67%)	10 (50%)	0.492
ODPD mg	25 (3–50)	20 (0–60)	0.458
Total CYC dose g	25 (0–250)	13 (0–68)	0.071
Total RTX dose g	4.0 (2–5)	4.0 (2–6)	0.780
1 g biannually RTX regimen	6 (40%)	8 (40%)	1.00
Baseline			
Total Ig	10.0 (8.2–18)	11.8 (6.7–21)	0.283
HypoG	0	0	NA
CD4	0.21 (0.06–0.29)	0.61 (0.31–1.4)	<0.001
Ratio	0.94 (0.27–2.3)	1.51 (0.55–3.0)	<0.001
At three months			
Total Ig	7.3 (4.8–15)	8.7 (6.6–12)	0.247
HypoG	3 (25%)	0	0.096
CD4	0.17 (0.09–1.4)	0.32 (0.17–0.89)	0.064
Ratio	0.81 (0.34–1.5)	1.12 (0.26–2.4)	0.096
At six months			
Total Ig	7.4 (4.5–16)	8.4 (4.1–12)	0.238
HypoG	3 (23%)	2 (11%)	0.374
CD4	0.27 (0.16–0.57)	0.43 (0.24–0.93)	< 0.001
Ratio	0.93 (0.38–1.3)	1.25 (0.42–4.5)	0.014
At 12 months			
Total Ig	7.1 (4.9–15)	8.5 (5.3–15)	0.158
HypoG	1 (7.1%)	2 (10%)	1.00
CD4	0.29 (0.17–0.64)	0.49 (0.19–1.4)	0.002
Ratio	0.85 (0.33–1.8)	1.4 (0.51–4.8)	0.010

Table 1 (continued).

	Low CD4 count 15 patients	Normal CD4 count 20 patients	p-value
At 18 months			
Total Ig	6.7 (4.7–17)	7.9 (4.9–14)	0.297
HypoG	3 (21%)	1 (5.9%)	0.304
CD4	0.35 (0.13–1.3)	0.49 (0.21–1.1)	0.042
Ratio	0.92 (0.40–1.9)	1.5 (0.53–6.0)	0.022
At 24 months			
Total Ig	6.7 (3.0–14)	7.5 (4.9–14)	0.179
HypoG	5 (33%)	3 (16%)	0.417
CD4	0.35 (0.06–1.0)	0.70 (0.08–1.3)	0.021
Ratio	0.84 (0.34–2.9)	1.40 (0.36–5.4)	0.120

Note:

ANCA, antineutrophil cytoplasmic antibodies; BVAS, Birmingham vasculitis activity score; CD, cluster of differentiation; CRP, C-reactive protein; CYC, cyclophosphamide; ESR, erythrocyte sedimentation rate; HypoG, hypogammaglobulinemia; Ig, immunoglobulins; mo, months; NA, not available; ODPD, oral daily prednisolone dose; RTX, rituximab.

normal serum levels of total Ig (11.2 and 12.6 g/l) at baseline. At the time of infection, CD4 cell count remained low (0.16 and $0.17 \times 10^9/l$) and total Ig had declined by to 4.8 and 7.5 g/l, respectively.

CD4 cell count and ratio in GPA patients who did not receive RTX maintenance

Four GPA patients (two men and two women) with a median age of 65 (14–79) years who had received a cumulative dose of 3 g (0–25) g of CYC were only administered RTX at induction and did not receive RTX maintenance.

The CD4 cell count and ratio decreased from 0.54 (0.26–0.98) at baseline to 0.36 (0.34 – 0.63) $\times 10^9/l$ at 24 months. The CD4/CD8 ratio decreased from baseline and became inverted at 24 months: from 1.4 (0.43–2.2) to 0.61 (0.45–2.0).

DISCUSSION

In GPA patients on long term RTX treatment, overall CD4 cell count and CD4/CD8 ratio initially decreased in the first three months and thereafter gradually increased independent of the ODPD at baseline, the CYC cumulative dose and the maintenance regimen. However in older patients, the inverted ratio at baseline remained unchanged after two years and was associated with lower levels of total Ig.

Early effect of rituximab on CD4 cell count

Prior to RTX treatment, 34 and 43% of GPA patients had respectively inverted CD4/CD8 ratio and decreased absolute numbers of CD4 cells. Age and the cumulative CYC dose were the most closely associated parameters, although these were not found statistically significant in this small cohort.

During RTX treatment, the early decrease in CD4 cell count seemed dependent of the baseline CD4 count. The higher the CD4 cell count was at baseline, the more CD4 cell

Table 2 Characteristics of GPA patients with inverted ratio at baseline against the rest of the cohort. Results are expressed in number (percentage) for categorical variables and median (range) for continuous variables. Differences were determined respectively by Fisher's exact test and Mann Whitney U test. Serum total immunoglobulin level and CD4 cell count expressed respectively in g/l and $\times 10^9/l$. Significant results are highlighted in bold.

	Inverted ratio 12 patients	Normal ratio 23 patients	p-value
Male	6 (50%)	13 (57%)	0.736
Age years	58 (37–79)	48 (14–75)	0.057
Disease duration prior RTX mo	116 (2–270)	47 (1–198)	0.263
BVAS at baseline	10.5 (4–21)	8.0 (0–21)	0.482
ESR mm/t	29 (3–118)	15 (3–100)	0.548
CRP mg/l	20 (4–135)	6 (4–115)	0.310
Creatinine μ mol/l	76 (58–244)	75 (43–819)	0.694
ANCA titers IU/ml	6 (0–531)	8 (1–213)	0.878
Kidney involvement	8 (67%)	13 (57%)	0.721
Lung involvement	8 (67%)	14 (61%)	1.00
Orbital-subglottic involvement	10 (83%)	15 (65%)	0.282
ODPD mg	23 (3–50)	23 (0–60)	0.719
Total CYC dose g	25 (0–250)	13 (0–79)	0.363
Total RTX dose g	4 (2–5)	4 (2–6)	0.263
1 g biannually RTX regimen	5 (42%)	9 (39%)	1.00
Baseline			
Total Ig	11.3 (8.3–18)	11.3 (6.7–21)	0.461
HypoG	0	0	NA
CD4	0.22 (0.06–0.79)	0.49 (0.15–1.4)	0.005
Ratio	0.61 (0.27–0.97)	1.42 (1.0–3.0)	< 0.001
At three months			
Total Ig	7.1 (4.8–15)	8.7 (5.0–12)	0.238
HypoG	1 (13%)	2 (12%)	1.00
CD4	0.20 (0.09–0.70)	0.29 (0.13–1.4)	0.264
Ratio	0.46 (0.34–1.1)	1.12 (0.26–2.4)	0.002
At six months			
Total Ig	6.7 (4.1–16)	9.1 (5.0–12)	0.017
HypoG	3 (27%)	2 (10%)	0.310
CD4	0.27 (0.16–0.42)	0.43 (0.18–0.93)	< 0.001
Ratio	0.55 (0.38–1.1)	1.25 (0.65–4.5)	< 0.001
At 12 months			
Total Ig	6.6 (5.3–15)	9.2 (4.9–15)	0.021
HypoG	1 (8.3%)	2 (9.1%)	1.00
CD4	0.28 (0.19–0.39)	0.50 (0.17–1.4)	< 0.001
Ratio	0.62 (0.33–1.3)	1.47 (0.77–4.8)	< 0.001

Table 2 (continued).

	Inverted ratio 12 patients	Normal ratio 23 patients	p-value
At 18 months			
Total Ig	6.5 (4.7–17)	8.6 (5.5–13)	0.012
HypoG	3 (30%)	1 (4.7%)	0.087
CD4	0.34 (0.15–0.48)	0.48 (0.13–1.3)	0.026
Ratio	0.53 (0.40–1.0)	1.63 (0.60–6.0)	< 0.001
At 24 months			
Total Ig	6.2 (3.0–14)	7.9 (4.0–14)	0.063
HypoG	5 (42%)	3 (14%)	0.098
CD4	0.34 (0.06–1.02)	0.69 (0.13–1.3)	0.007
Ratio	0.56 (0.34–1.5)	1.64 (0.60–5.4)	< 0.001

Note:

ANCA, antineutrophil cytoplasmic antibodies; BVAS, Birmingham vasculitis activity score; CD, cluster of differentiation; CRP, C-reactive protein; CYC, cyclophosphamide; ESR, erythrocyte sedimentation rate; HypoG, hypogammaglobulinemia; Ig, immunoglobulins; mo, months; NA, not available; ODPD, oral daily prednisolone dose; RTX, rituximab.

Table 3 Odds ratio for inverted CD4/CD8 ratio at 24 months in GPA patients receiving rituximab maintenance. All values were determined at rituximab initiation and were analysed with an unadjusted and multivariable logistic regression models with backward Wald selection (removal if $p < 0.10$). Significant results are highlighted in bold.

	Unadjusted analysis			Multivariable analysis		
	OR	95% CI	p-value	OR	95% CI	p-value
Men	1.06	0.27–4.24	0.934			
Age (y)	1.10	1.02–1.18	0.012	1.09	1.01–1.18	0.027
Disease duration (mo)	1.01	0.99–1.02	0.075	1.01	0.99–1.03	0.089
BVAS	1.13	0.96–1.32	0.135			
ESR (mm/h)	1.03	1.00–1.05	0.024	1.03	0.99–1.06	0.098
CRP (mg/l)	1.02	1.00–1.04	0.044			0.705
Creatinine ($\mu\text{mol/l}$)	1.02	0.99–1.05	0.081			0.164
ANCA titers (IU/ml)	1.03	0.98–1.08	0.184			
ODPD (mg/d)	1.04	0.98–1.09	0.138			
CYC cumulative dose (g)	1.01	0.99–1.03	0.388			
IgG (g/l)	1.13	0.84–1.52	0.428			
IgA (g/l)	1.20	0.50–2.93	0.682			
IgM (g/l)	2.21	0.70–7.00	0.177			
Total Ig (g/l)	1.11	0.89–1.37	0.357			

Note:

ANCA, antineutrophil cytoplasmic antibodies; BVAS, Birmingham vasculitis activity score; CI, confidence interval; CRP, C-reactive protein; CYC, cyclophosphamide; ESR, erythrocyte sedimentation rate; Ig, immunoglobulins; mo, months; ODPD, oral daily prednisolone dose; OR, odds ratio; y, years.

count declined at three months. GPA patients with normal CD4 cell count (mean $0.67 \times 10^9/\text{L}$ at baseline) had a 40% decrease at three months while GPA patients with low CD4 cell count (mean $0.19 \times 10^9/\text{L}$ at baseline) had an 89% increase.

Table 4 Characteristics of the GPA patients receiving RTX 1 g biannually as maintenance treatment compared with the rest of the cohort. Differences between categorical and continuous variables are determined respectively by Fisher's exact test and Mann Whitney U test. Serum total immunoglobulin level and CD4 cell count expressed respectively in g/L and $\times 10^9/L$.

	1 g biannually regimen 14 patients	Other regimens 21 patients	p-value
Male	9 (64%)	10 (48%)	0.491
Age y	50	47	0.702
Total CYC dose g	43	25	0.274
Total RTX dose g	4.9	3.7	< 0.001
Baseline			
Total Ig	12.2	10.9	0.342
HypoG	0	0	NA
CD4	0.39	0.51	0.474
Ratio	1.31	1.37	0.881
At three months			
Total Ig	8.4	8.6	0.426
HypoG	3 (25%)	0	0.096
CD4	0.25	0.46	0.194
Ratio	0.80	1.11	0.123
At six months			
Total Ig	8.8	7.9	0.600
HypoG	2 (15%)	3 (16%)	1.00
CD4	0.41	0.41	0.667
Ratio	1.51	1.20	0.421
At 12 months			
Total Ig	8.5	8.9	0.594
HypoG	1 (7.7%)	2 (9.5%)	1.00
CD4	0.45	0.49	0.600
Ratio	1.72	1.32	0.834
At 18 months			
Total Ig	8.3	8.4	0.666
HypoG	4 (31%)	0	0.023
CD4	0.37	0.57	0.059
Ratio	1.78	1.41	0.953
At 24 months			
Total Ig	7.5	8.2	0.650
HypoG	3 (21%)	5 (25%)	1.00
CD4	0.52	0.61	0.522
Ratio	1.91	1.42	0.823

Note:

CD, cluster of differentiation; CYC, cyclophosphamide; HypoG, hypogammaglobulinemia; Ig, immunoglobulins; RTX, rituximab.

The same pattern was observed in RA (*Mélet et al., 2013; Thurlings et al., 2008; Feuchtenberger et al., 2008*) and in systemic lupus erythematosus (SLE) patients (*Sfikakis et al., 2005*), but not in renal transplantation (*Kamburova et al., 2014*).

In RA, CD4 cell count decreased by 37% at three months from a mean of $1.25 \times 10^9/l$ at baseline (Mélet *et al.*, 2013), remained unchanged at four months from a mean of $0.93 \times 10^9/l$ at baseline (Thurlings *et al.*, 2008) and increased by 14% from a mean of $0.63 \times 10^9/l$ at baseline during the first three months (Feuchtenberger *et al.*, 2008). SLE patients had a 46% increase in CD4 cell count one month after RTX initiation from a mean of $0.43 \times 10^9/l$ at baseline (Sfikakis *et al.*, 2005). However, there were no effect of a single dose of RTX (375 mg/m^2) on the CD4 and CD8 cell counts as well as the percentage of the different CD4 cell subsets including regulatory T cells at three and 24 months in renal transplant recipients concomitantly treated with tacrolimus and mycophenolate mofetil during the first six months (Kamburova *et al.*, 2014).

Rituximab failed to normalise the CD4/CD8 ratio at 24 months

RTX induction and maintenance failed to normalise the CD4/CD8 ratio in GPA patients with an inverted ratio at baseline, although CD4 cell counts recovered. Being 10 years older at baseline doubled the risk of inversion of the CD4/CD8 ratio at 24 months. This suggests a relative increase in CD8+ lymphocytes in older GPA patients receiving RTX. Still, it remains unclear how absolute CD4 cell count and ratio related to changes in disease activity, subsets of CD4 and CD8 cells or the combination of toxic drug effects.

GPA patients with inverted ratio after 24 months of RTX maintenance seemed to have more disease activity prior to RTX, more kidney involvement and higher inflammation parameters, in accordance to a previous report from Iking-Konert *et al.* (2008). They also had lower serum Ig during the course of our study, suggesting a more profound B cell-depleting effect.

Limitations of the study

Our results should be interpreted with caution given the small size of the study cohort and the inherent risk of selection bias. Most of our GPA patients received RTX for refractory and relapsing disease, indicating a selected group who had received high cumulative dose of CYC and prolonged corticosteroids exposure prior to RTX. In addition, we only followed CD4 and CD8 counts in patients, and did not study important T cell subsets such as regulatory T cells.

CONCLUSIONS

Our study suggests that the early decrease in CD4 after induction with RTX seemed dependent of the baseline CD4 count. Overall, CD4 cell count and CD4/CD8 ratio in GPA patients increased over time during RTX with no discernible impact of other immunosuppressive therapy. Increase in CD4 was not always followed by an increase in CD4/CD8 ratio, especially for a subgroup of older patients whom CD4/CD8 ratio remained inverted. Inverted CD4/CD8 ratio associated with lower Ig levels during maintenance with RTX.

Our study suggest that GPA patients with inverted CD4/CD8 ratio seemed to have a more profound B cell-depleting effect of RTX and a relative increase in CD8+ lymphocytes. CD4/CD8 ratio could be an important marker of a patient's net status of

immunodeficiency during RTX, since inverted CD4/CD8 ratio is a common surrogate marker of immunosenescence of impaired responses to vaccination and infections due to the loss of repertoire diversity (*Blackman & Woodland, 2011*).

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

The authors received no funding for this work.

Competing Interests

The authors declare that they have no competing interests.

Author Contributions

- Emilio Besada analyzed the data, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.
- Johannes C. Nossent wrote the paper, reviewed drafts of the paper.

Human Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

Data are collected from the Vasculitis Registry in Northern Norway (NordNorsk vaskulitt register).

The study did not require formal ethical approval and conformed to the standards currently applied in Norway.

Data Deposition

The following information was supplied regarding data availability:

The raw data is available at Dataverse, Harvard University: <http://dx.doi.org/10.7910/DVN/6U2KJ0>.

REFERENCES

- Abdulahad WH, van der Geld YM, Stegeman CA, Kallenberg CGM. 2006.** Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis. *Kidney International* 70(5):938–947 DOI 10.1038/sj.ki.5001670.
- Berden AE, Kallenberg CGM, Savage COS, Yard BA, Abdulahad WH, de Heer E, Bruijn JA, Bajema IM. 2009.** Cellular immunity in Wegener's granulomatosis: characterizing T lymphocytes. *Arthritis & Rheumatism* 60(6):1578–1587 DOI 10.1002/art.24576.
- Besada E, Koldingsnes W, Nossent J. 2012.** Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center. *QJM* 105(6):545–550 DOI 10.1093/qjmed/hcs015.
- Besada E, Koldingsnes W, Nossent JC. 2013.** Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. *Rheumatology* 52(11):2041–2047 DOI 10.1093/rheumatology/ket257.
- Besada E, Koldingsnes W, Nossent JC. 2014.** Serum immunoglobulin levels and risk factors for hypogammaglobulinemia during long-term maintenance therapy with Rituximab in

- patients with Granulomatosis with polyangiitis. *Rheumatology* 53(10):1818–1824 DOI 10.1093/rheumatology/keu194.
- Blackman MA, Woodland DL. 2011.** The narrowing of the CD8 T cell repertoire in old age. *Current Opinion in Immunology* 23(4):537–542 DOI 10.1016/j.coi.2011.05.005.
- Cartin-Ceba R, Golbin JM, Keogh KA, Peikert T, Sánchez-Menéndez M, Ytterberg SR, Fervenza FC, Specks U. 2012.** Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. *Arthritis & Rheumatism* 64(11):3770–3778 DOI 10.1002/art.34584.
- Edwards JCW, Cambridge G. 2006.** B-cell targeting in rheumatoid arthritis and other autoimmune diseases. *Nature Reviews Immunology* 6(5):394–403 DOI 10.1038/nri1838.
- Feuchtenberger M, Müller S, Roll P, Waschbisch A, Schäfer A, Kneitz C, Wiendl H, Tony H-P. 2008.** Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. *The Open Rheumatology Journal* 2(1):81–88 DOI 10.2174/1874312900802010081.
- Furuta S, Jayne D. 2014.** Emerging therapies in antineutrophil cytoplasm antibody-associated vasculitis. *Current Opinion in Rheumatology* 26(1):1–6 DOI 10.1097/BOR.0000000000000005.
- Gottenberg J-E, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, Dougados M, Flipo RM, Godeau B, Guillevin L, Loët XL, Hachulla E, Schaevebeke T, Sibilia J, Baron G, Mariette XL, AutoImmunity and Rituximab registry and French Society of Rheumatology. 2010.** Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. *Arthritis & Rheumatism* 62(9):2625–2632 DOI 10.1002/art.27555.
- Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P, Quémeneur T, Blanchard-Delaunay C, Godmer P, Puéchal X, Carron P-L, Hatron P-Y, Limal N, Hamidou M, Ducret M, Dugas E, Papo T, Bonnotte B, Mahr A, Ravaud P, Mouthon L, French Vasculitis Study Group. 2014.** Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. *New England Journal of Medicine* 371(19):1771–1780 DOI 10.1056/NEJMoa1404231.
- Ikeda M, Tsuru S, Watanabe Y, Kitahara S, Inouye T. 1992.** Reduced CD4-CD8 T cell ratios in patients with Wegener's granulomatosis. *Journal of Clinical & Laboratory Immunology* 38(3):103–109.
- Iking-Konert C, Vogl T, Prior B, Wagner C, Sander O, Bleck E, Ostendorf B, Schneider M, Andrassy K, Hänsch GM. 2008.** T lymphocytes in patients with primary vasculitis: expansion of CD8+ T cells with the propensity to activate polymorphonuclear neutrophils. *Rheumatology* 47(5):609–616 DOI 10.1093/rheumatology/ken028.
- Jones RB, Tevaert JWC, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DRW, European Vasculitis Study Group. 2010.** Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. *New England Journal of Medicine* 363(3):211–220 DOI 10.1056/NEJMoa0909169.
- Kallenberg CGM. 2011.** Pathogenesis of ANCA-associated vasculitides. *Annals of the Rheumatic Diseases* 70(Suppl 1):i59–i63 DOI 10.1136/ard.2010.138024.
- Kamburova EG, Koenen HJPM, van den Hoogen MWF, Baas MC, Joosten I, Hilbrands LB. 2014.** Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy. *PLoS ONE* 9(11):e112658 DOI 10.1371/journal.pone.0112658.

- Leandro MJ, de la Torre I. 2009.** Translational mini-review series on B cell-directed therapies: the pathogenic role of B cells in autoantibody-associated autoimmune diseases—lessons from B cell-depletion therapy. *Clinical & Experimental Immunology* 157(2):191–197 DOI 10.1111/j.1365-2249.2009.03978.x.
- Makatsori M, Kiani-Alikhan S, Manson A, Verma N, Leandro M, Gurugama NP, Longhurst HJ, Grigoriadou S, Buckland M, Kanfer E, Hanson S, Ibrahim MA, Grimbacher B, Chee R, Seneviratne SL. 2014.** Hypogammaglobulinaemia after rituximab treatment—incidence and outcomes. *QJM* 107(10):821–828 DOI 10.1093/qjmed/hcu094.
- Marinaki S, Kälsch A-I, Grimminger P, Breedijk A, Birck R, Schmitt WH, Weiss C, van der Woude FJ, Yard BA. 2006.** Persistent T-cell activation and clinical correlations in patients with ANCA-associated systemic vasculitis. *Nephrology Dialysis Transplantation* 21(7):1825–1832 DOI 10.1093/ndt/gfl097.
- Mélet J, Mulleman D, Goupille P, Ribourtout B, Watier H, Thibault G. 2013.** Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. *Arthritis & Rheumatism* 65(11):2783–2790 DOI 10.1002/art.38107.
- Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P. 2009.** The late adverse events of rituximab therapy—rare but there! *Leukemia & Lymphoma* 50(7):1083–1095 DOI 10.1080/10428190902934944.
- Sailler L, Attane C, Michenot F, Canonge J-M, Rostaing L, Arlet-Suau E, Arlet P, Launay F, Montastruc J-L, Lapeyre-Mestre M. 2008.** Rituximab off-label use for immune diseases: assessing adverse events in a single-centre drug-utilization survey. *British Journal of Clinical Pharmacology* 66(2):320–322 DOI 10.1111/j.1365-2125.2008.03193.x.
- Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM. 2005.** Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. *Arthritis & Rheumatism* 52(2):501–513 DOI 10.1002/art.20858.
- Smith RM, Jones RB, Guerry M-J, Laurino S, Catapano F, Chaudhry A, Smith KGC, Jayne DRW. 2012.** Rituximab for remission maintenance in relapsing ANCA-associated vasculitis. *Arthritis & Rheumatism* 64(11):3760–3769 DOI 10.1002/art.34583.
- Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CGM, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group. 2010.** Rituximab versus cyclophosphamide for induction of remission in ANCA-associated vasculitis. *New England Journal of Medicine* 363(3):221–232 DOI 10.1056/NEJMoa0909905.
- Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP. 2008.** Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. *Annals of the Rheumatic Diseases* 67(7):917–925 DOI 10.1136/ard.2007.080960.
- Wilde B, Thewissen M, Damoiseaux J, van Paassen P, Witzke O, Tervaert JWC. 2010.** T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells? *Arthritis Research & Therapy* 12(1):204 DOI 10.1186/ar2923.